NAG6 Inhibitors
NAG6 inhibitors, belonging to the class of small molecules, are compounds designed to modulate a specific biochemical pathway by selectively inhibiting the activity of N-acetylglucosaminyltransferase 6 (NAG6). NAG6 is an essential enzyme involved in glycosylation processes within cells, particularly in the Golgi apparatus, where it catalyzes the transfer of N-acetylglucosamine (GlcNAc) residues to target substrates. The inhibition of NAG6 by these molecules disrupts the glycosylation pattern of proteins, impacting various cellular functions and signaling pathways.
The structural diversity of NAG6 inhibitors allows for versatile interactions with the enzyme, targeting specific binding sites crucial for its catalytic activity. Researchers have explored the synthesis of novel NAG6 inhibitors with the aim of elucidating the molecular mechanisms underlying glycosylation and its implications in cellular processes. Understanding the structural nuances of these inhibitors provides valuable insights into the intricate network of glycosylation pathways and offers potential avenues for modulating cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin acts by directly binding to FKBP12 and then targeting mTOR complex 1 (mTORC1), leading to the inhibition of mTOR signaling. Since mTOR can regulate protein synthesis, its inhibition can decrease the functional activity of NAG6 if NAG6 synthesis is mTOR-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphatidylinositol 3-kinase (PI3K), LY294002 impedes the PI3K/Akt/mTOR pathway. By doing so, it prevents the phosphorylation and activation of mTOR, which could indirectly decrease NAG6 synthesis if it is under the control of this signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. Similar to LY294002, it inhibits the PI3K/Akt/mTOR cascade, which can result in reduced activity of downstream proteins, potentially including NAG6 if its expression is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, effectively blocking the MAPK/ERK pathway. If NAG6 activity or stability is modulated by ERK signaling, the inhibition of this pathway by U0126 could lead to reduced function of NAG6. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which in turn prevents the activation of ERK. This compound can decrease NAG6 functional activity by inhibiting the MAPK/ERK pathway if NAG6 is downstream of this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway is involved in the stress response and inflammation. Inhibition of this pathway by SB203580 could result in decreased activation of NAG6 if it is implicated in the same cellular responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This compound is an inhibitor of JNK, which plays a role in stress response, apoptosis, and transcriptional regulation. If NAG6 is regulated by JNK signaling, SP600125 could indirectly reduce its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting ADP-ribosylation factor (Arf). If the transport and proper localization of NAG6 are essential for its activity, Brefeldin A could decrease its functional activity by disrupting these processes. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A binds to cyclophilins and inhibits calcineurin, thereby blocking NFAT (nuclear factor of activated T-cells) translocation to the nucleus. If NAG6 activity is modulated by NFAT-mediated signaling, this inhibition could lead to a decrease in NAG6 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If NAG6 is regulated through proteasomal degradation, MG132 could indirectly affect its functional activity by stabilizing regulatory proteins that inhibit NAG6. | ||||||